James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.
Shanna Miranti, MPAS, PA-C: Assessing Treatment Efficacy in Patients with Vitiligo
Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.
James Del Rosso, DO: Systemic Atopic Dermatitis Treatment Updates from SCALE 2024
We checked in with JCAD’s Clinical Editor in Chief, Dr. Jim Del Rosso, for a recap of the systemic therapies discussed during his atopic dermatitis update session presented at SCALE 2024. Stay tuned for an upcoming video on topical treatments discussed during his session!
Raj Chovatiya, MD, PhD: Atopic Dermatitis Patient Counseling for Moisturization
Dr. Chovatiya discusses the effectiveness of providing a moisturizer in combination with a topical or systemic therapy to achieve clear skin regardless of disease severity.
Andrea Nguyen, PA-C, MS: Treatment Education for Patients with Atopic Dermatitis
Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.